Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram Oxalate and VNS for Depression and Rheumatoid Arthritis
NCT04037111Unknown
- Sponsor
- Xijing Hospital
- Start
- Jul 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Escitalopram oxalate oral solution in major depressive disorder (MDD) and rheumatoid arthritis (RA) (3 arms), sponsored by Xijing Hospital. Primary endpoint: Hamilton Depression Rating Scale at 8 weeks. Status: unknown.
02
Drugs
Escitalopram oxalate oral solution
03
Conditions
major depressive disorder (MDD)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04037111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04037111.